A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients
A phase 3 trial of AZD0486 in follicular lymphoma, run by AstraZeneca, now recruiting.
Overview
A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients is a phase 3 interventional study registered as NCT06549595 by AstraZeneca, with 1018 participants planned, started 2024-08-07 and due to reach its primary completion in 2031-11-26. Interventions recorded: Surovatamig, R-CHOP, R-CVP, BR. Conditions listed: Untreated Follicular Lymphoma. No results are recorded here; the registry entry is the source.
Setting
A Phase III, Multicentre, Randomised, Open-label Study to Compare the Efficacy and Safety of AZD0486 Plus Rituximab Versus Chemotherapy Plus Rituximab in Previously Untreated Participants With Follicular Lymphoma (SOUNDTRACK-F1)
Phase
Phase 3
Sponsor
AstraZeneca
Registry
Enrolled
1018
Similar pages
not linked directly; found by shared links- TrialSurovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL
Shares AZD0486, Follicular lymphoma, AstraZeneca.
- TrialAZD0486 1L Therapy for Elderly or Unfit Participants With LBCL
Shares AZD0486, AstraZeneca.
- TrialSurovatamig as Consolidation Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated Immunoglobulin He
Shares AZD0486, AstraZeneca.
- TrialA Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies
Shares AZD0486, AstraZeneca.